Sai Gourisankar

Sai Gourisankar

Auto-generated profile, based on publicly available information

Sai Gourisankar

Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2024 in Science
Verified
Journal Article
Closed access
RSRoman C. Sarott
Roman C. Sarott
SGSai Gourisankar
Sai Gourisankar
BKBasel Karim
Basel Karim
SNSabin Nettles
Sabin Nettles
HYHaopeng Yang
Haopeng Yang
NGNathanael S. Gray
Nathanael S. Gray
Kinases are critical regulators of cellular function that are commonly implicated in the mechanisms underlying disease. Most drugs that target kinases are molecules that inhibit their catalytic activity, but here we used chemically induced proximity to convert kinase inhibitors into activators of therapeutic genes. We synthesized bivalent molecules that link ligands of the transcription factor B cell lymphoma 6 (BCL6) to inhibitors of cyclin-dependent kinases (CDKs). These molecules relocalized CDK9 to BCL6-bound DNA and directed phosphorylation of RNA polymerase II. The resulting expression of pro-apoptotic, BCL6-target genes caused killing of diffuse large B cell lymphoma cells and specific ablation of the BCL6-regulated germinal center response. Genomics and proteomics corroborated a gain-of-function mechanism in which global kinase activity was not inhibited but rather redirected. Thus, kinase inhibitors can be used to context-specifically activate transcription.

5 May 2020 in ACS Chemical Biology
Verified
Journal Article
Closed access
ECEmma J. Chory
Emma J. Chory
JKJacob Kirkland
Jacob Kirkland
CCChiung-Ying Chang
Chiung-Ying Chang
VDVincent D. D’aNdrea
Vincent D. D’aNdrea
SGSai Gourisankar
Sai Gourisankar
GCGerald R. Crabtree
Gerald R. Crabtree

17 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MNMeredith N. Nix
Meredith N. Nix
SGSai Gourisankar
Sai Gourisankar
RSRoman C. Sarott
Roman C. Sarott
BDBrendan G. Dwyer
Brendan G. Dwyer
SNSabin. A. Nettles
Sabin. A. Nettles
GCGerald R. Crabtree
Gerald R. Crabtree
SUMMARY: Developing cancer therapies that induce robust death of the malignant cell is critical to prevent relapse. Highly effective strategies, such as immunotherapy, exemplify this observation. Here we provide the structural and molecular underpinnings for an approach that leverages chemical induced proximity to produce specific cell killing of diffuse large B cell lymphoma, the most common non-Hodgkin’s lymphoma. We develop KAT-TCIPs (lysine acetyltransferase transcriptional/epigenetic chemical inducers of proximity) that redirect p300 and CBP to activate programmed cell death genes normally repressed by the oncogenic driver, BCL6. Acute treatment rapidly reprograms the epigenome to initiate apoptosis and repress c-MYC. The crystal structure of the chemically induced p300-BCL6 complex reveals how chance interactions between the two proteins can be systematically exploited to produce the exquisite potency and selectivity of KAT-TCIPs. Thus, the malignant function of an oncogenic driver can be co-opted to activate robust cell death, with implications for precision epigenetic therapies.

14 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SGSai Gourisankar
Sai Gourisankar
WWWendy Wenderski
Wendy Wenderski
JPJ. A. Paulo
J. A. Paulo
SKSam H Kim
Sam H Kim
KRKyra Roepke
Kyra Roepke
GCGerald Crabtree
Gerald Crabtree
Genes encoding subunits of the SWI/SNF or BAF ATP-dependent chromatin remodeling complex are among the most enriched for deleterious de novo mutations in intellectual disabilities and autism spectrum disorder, but the causative molecular pathways are not fully known 1,2 . Synaptic activity in neurons is critical for learning and memory and proper neural development 3 . Neural activity prompts calcium influx and transcription within minutes, facilitated in the nucleus by various transcription factors (TFs) and chromatin modifiers 4 . While BAF is required for activity-dependent developmental processes such as dendritic outgrowth 5–7 , the immediate molecular consequences of neural activity on BAF complexes and their functions are unknown. Here we mapped minute-scale biochemical consequences of neural activity, modeled by membrane depolarization of embryonic mouse primary cortical neurons, on BAF complexes. We used acute chemical perturbations of BAF ATPase activity and kinase signaling to define the activity-dependent effects on BAF complexes and activity-dependent BAF functions. Our studies found that BAF complexes change in subunit composition and are selectively phosphorylated within 10 minutes of depolarization. Increased levels of the core PBAF subunit Baf200/ Arid2 , uniquely containing an RFX-like DNA-binding domain, are concurrent with ATPase-dependent opening of chromatin at RFX/X-box motifs. Changes in BAF composition and phosphorylation lead to the regulation of chromatin accessibility for critical neurogenesis TFs. These biochemical effects are a convergent phenomenon downstream of multiple growth factor signaling pathways in mouse neurons and fibroblasts suggesting that BAF integrates signaling information from the membrane. In support of such a membrane-to-nucleus signaling cascade, we also identified a BAF-interacting kinase, Dclk2, whose inhibition attenuates BAF phosphorylation selectively. Our findings support a direct role of BAF complexes in responding to synaptic activity to regulate TF binding and transcription.

27 November 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MBMichael J. Bond
Michael J. Bond
RGRyan P. Golden
Ryan P. Golden
GDGiulia DiGiovanni
Giulia DiGiovanni
BHBriana Howard
Briana Howard
RSRoman C. Sarott
Roman C. Sarott
KSKimberly Stegmaier
Kimberly Stegmaier

25 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
RSRoman C Sarott
Roman C Sarott
SGSai P Gourisankar
Sai P Gourisankar
BKBasel Aydon Karim
Basel Aydon Karim
SNSabin Nettles
Sabin Nettles
HYHaopeng Yang
Haopeng Yang
NGNathanael S. Gray
Nathanael S. Gray
Protein kinases are disease drivers whose therapeutic targeting traditionally centers on inhibition of enzymatic activity. Here chemically induced proximity is leveraged to convert kinase inhibitors into context-specific activators of therapeutic genes. Bivalent molecules that link ligands of the transcription factor B-cell lymphoma 6 (BCL6) to ATP-competitive inhibitors of cyclin-dependent kinases (CDKs) were developed to re-localize CDK to BCL6-bound loci on chromatin and direct phosphorylation of RNA Pol II. The resulting BCL6-target proapoptotic gene expression translated into killing of diffuse large B-cell lymphoma (DLBCL) cells at 72 h with EC50s of 0.9 – 10 nM and highly specific ablation of the BCL6-regulated germinal center response in mice. The molecules exhibited 10,000-fold lower cytotoxicity in normal lymphocytes and are well tolerated in mice. Genomic and proteomic evidence corroborated a gain-of-function mechanism where, instead of global enzyme inhibition, a fraction of total kinase activity is borrowed and re-localized to BCL6-bound loci. The strategy demonstrates how kinase inhibitors can be used to context-specifically activate transcription, accessing new therapeutic space.